Amphastar Director Sells 16,679 Shares for $441,800

Published: Tuesday, December 23, 2025 at 3:07 pm

Amphastar Director Sells Shares in Open Market Transaction

In a recent transaction, Floyd Petersen, a director at Amphastar Pharmaceuticals, sold 16,679 shares of the company's common stock for approximately $441,800. The sale, disclosed in a SEC Form 4 filing, involved shares acquired through the exercise of stock options. The shares were sold immediately after being acquired.

The transaction occurred on November 13, 2025, with the shares priced at around $26.49 each. The stock closed at $26.37 on the same day. This sale is notably larger than Petersen's historical median sell-only transaction. Following the sale, Petersen retains 75,531 shares, valued at approximately $2.0 million as of the transaction date. This represents a 4% reduction in his direct holdings since May 2024.

Amphastar Pharmaceuticals is a mid-cap biopharmaceutical company specializing in injectable and inhalation products. The company's portfolio includes both generic and proprietary drugs, targeting the U.S., China, and France markets. The company's stock had declined by 42% over the prior 12 months as of the transaction date. Amphastar has a long-standing share-repurchase program, having bought back over 14.1 million shares since 2016.

BNN's Perspective:

While insider selling can raise questions, it's important to consider the context. In this case, the sale appears to be a standard exercise of stock options, a common practice. The director still holds a significant stake in the company. Investors should monitor the company's performance and overall market trends to make informed decisions.

Keywords: Amphastar Pharmaceuticals, AMPH, stock sale, insider trading, Floyd Petersen, SEC Form 4, stock options, biopharmaceutical, generic drugs, proprietary drugs, share repurchase, market analysis

Full Story